GLP-1 Receptor Agonist

FDA Approved

Exenatide

Byetta / Bydureon

Manufactured by AstraZeneca · Subcutaneous injection

Avg Weight Loss

~2-4% body weight (not FDA-approved for weight management; weight loss is a secondary benefit)

Dosing

Twice daily (Byetta) or Once weekly (Bydureon BCise)

Brand Cost

$700-900

Compounded

Not widely compounded

How It Works

Exenatide is a synthetic version of exendin-4, a peptide originally discovered in the saliva of the Gila monster (Heloderma suspectum). It shares 53% homology with human GLP-1 and is resistant to degradation by DPP-4 enzyme. It activates GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. Bydureon uses microsphere technology for sustained release.

Byetta (Type 2 Diabetes (twice daily)) Bydureon (Type 2 Diabetes (once weekly))

Dosing & Titration

byetta

5mcg twice daily 10mcg twice daily

bydureon

2mg once weekly

Titration Protocol

Byetta: Start at 5mcg twice daily (within 60 minutes before morning and evening meals) for at least 1 month, then may increase to 10mcg twice daily. Bydureon: 2mg once weekly, no titration required.

Common Side Effects

Common Nausea Common Vomiting Common Diarrhea Common Dizziness Common Headache Common Dyspepsia Common Constipation Common Injection site reactions (especially Bydureon: nodules, pruritus)

Serious Risks

Pancreatitis (rare)

Thyroid C-cell tumors (observed in rodent studies with extended-release; relevance to humans unknown)

Acute kidney injury

Hypoglycemia (when used with sulfonylureas)

Serious allergic reactions

Injection site reactions (Bydureon: subcutaneous nodules)

Cost Comparison

Brand Name

$700-900

per month

Compounded

Not widely compounded

per month

Pharmacy Options

Brand (retail)

Insurance Coverage

Generally covered for Type 2 Diabetes. May face step therapy requirements (try metformin first). Coverage has declined as newer GLP-1 agents have gained market share.

Pros & Cons

Advantages

First-in-class GLP-1 RA (most clinical experience)
Lower cost than newer agents
Bydureon BCise is a simple autoinjector with no mixing
Available as generic in some markets

Disadvantages

Twice daily dosing (Byetta) is burdensome
Least weight loss among GLP-1 class
Injection site nodules with Bydureon
Failed to demonstrate significant cardiovascular benefit
Largely superseded by more effective agents
Contraindicated in severe renal impairment

Clinical Evidence

Clinical Trial Programs

EXSCEL (cardiovascular outcomes trial), DURATION program (extended-release studies 1-8)

exscel

Did not reach statistical significance for MACE reduction (HR 0.91, p=0.06), but showed non-inferiority for cardiovascular safety

duration5

Bydureon showed superior A1C reduction vs Byetta twice daily (-1.6% vs -0.9%)

Contraindications

Personal or family history of medullary thyroid carcinoma (MTC) (Bydureon only)
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) (Bydureon only)
Known hypersensitivity to exenatide or any excipients
Severe renal impairment (eGFR <30) or end-stage renal disease

Find providers offering Exenatide near you

Compare pricing, pharmacy sourcing, and clinical oversight across verified providers prescribing Byetta and Bydureon.

Compare Providers → Search by Location

Get weekly GLP-1 medication updates

New research, pricing changes, and provider comparisons — delivered to your inbox.

Compare all GLP-1 medications

See how Exenatide stacks up against other GLP-1 options. Compare efficacy, cost, side effects, and dosing schedules side by side.

View All Medications →